Atrium Therapeutics, Inc. (RNA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
10578 Science Center Drive
San Diego, CA 92121
United States of America (the)
Phone
619 876 0700
Sector
Healthcare
Industry
Biotechnology
Employees
511
First IPO Date
February 27, 2026
| Name | Title | Pay | Year Born |
| Kathleen Gallagher | President, CEO & Director | 0 | 1982 |
| Husam Younis | Chief Scientific Officer | 0 | 1974 |
| Brendan Winslow | Chief Financial Officer | 0 | 1988 |
| Steven George Hughes | Chief Medical Officer | 0 | 1968 |
| Rocio Martin Hoyos | Chief Strategy Officer | 0 | 1983 |
| Stephanie Kenney | Chief Corporate Affairs Officer | 0 | 1978 |
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.